1. Introduction
1.1 Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Market Insights
2.2 Market Attractiveness
3. Research Methodology
3.1 Secondary Research
3.2 Primary Research
- 3.2.1 Data Triangulation and Validation
4. Asia Pacific Cancer Hormone Therapy Market Landscape
4.1 Overview
4.3 Ecosystem Analysis
- 4.3.1 List of Vendors in the Value Chain
5. Asia Pacific Cancer Hormone Therapy Market – Key Market Dynamics
5.1 Market Drivers
5.2 Market Restraints
5.3 Market Opportunities
5.4 Future Trends
5.5 Impact of Drivers and Restraints
6. Asia Pacific Cancer Hormone Therapy Market Regional Analysis
6.2 Asia Pacific Cancer Hormone Therapy Market Revenue 2021-2031 (US$ Million)
6.3 Asia Pacific Cancer Hormone Therapy Market Forecast Analysis
7. Asia Pacific Cancer Hormone Therapy Market Analysis – by Drug Class
7.1 GnRH Analogs
- 7.1.1 Overview
- 7.1.2 GnRH Analogs: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.2 GnRH Antagonists
- 7.2.1 Overview
- 7.2.2 GnRH Antagonists: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.3 Androgen Receptor Antagonists
- 7.3.1 Overview
- 7.3.2 Androgen Receptor Antagonists: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.4 Aromatase Inhibitors
- 7.4.1 Overview
- 7.4.2 Aromatase Inhibitors: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.5 Selective Estrogen Receptor Modulators
- 7.5.1 Overview
- 7.5.2 Selective Estrogen Receptor Modulators: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.6 Estrogen Receptor Antagonists
- 7.6.1 Overview
- 7.6.2 Estrogen Receptor Antagonists: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.7 Thyroid Hormone Therapy
- 7.7.1 Overview
- 7.7.2 Thyroid Hormone Therapy: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
7.8 Other Drug Classes
- 7.8.1 Overview
- 7.8.2 Other Drug Classes: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8. Asia Pacific Cancer Hormone Therapy Market Analysis – by Cancer Type
8.1 Breast Cancer
- 8.1.1 Overview
- 8.1.2 Breast Cancer: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.2 Prostate Cancer
- 8.2.1 Overview
- 8.2.2 Prostate Cancer: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.3 Endometrial Cancer
- 8.3.1 Overview
- 8.3.2 Endometrial Cancer: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.4 Ovarian Cancer
- 8.4.1 Overview
- 8.4.2 Ovarian Cancer: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.5 Thyroid Cancer
- 8.5.1 Overview
- 8.5.2 Thyroid Cancer: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
8.6 Other Cancer Types
- 8.6.1 Overview
- 8.6.2 Other Cancer Types: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9. Asia Pacific Cancer Hormone Therapy Market Analysis – by Route of Administration
9.1 Oral
- 9.1.1 Overview
- 9.1.2 Oral: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.2 Injectable
- 9.2.1 Overview
- 9.2.2 Injectable: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
9.3 Implantable
- 9.3.1 Overview
- 9.3.2 Implantable: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10. Asia Pacific Cancer Hormone Therapy Market Analysis – by Sales Channel
10.1 Hospitals
- 10.1.1 Overview
- 10.1.2 Hospitals: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.2 Cancer Treatment Centers
- 10.2.1 Overview
- 10.2.2 Cancer Treatment Centers: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.3 Specialty Clinics
- 10.3.1 Overview
- 10.3.2 Specialty Clinics: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
10.4 Retail Pharmacies
- 10.4.1 Overview
- 10.4.2 Retail Pharmacies: Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast, 2021-2031 (US$ Million)
11. Asia Pacific Cancer Hormone Therapy Market – Asia Pacific Analysis
11.1 Overview
11.2 Asia Pacific
- 11.2.1 Asia Pacific Cancer Hormone Therapy Market Breakdown, by Key
Country, 2025 and 2031 (%)
- 11.2.1.1 Asia Pacific Cancer Hormone Therapy Market – Revenue and
Forecast Analysis – by Country
- 11.2.1.1 China:
Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.1.1 China: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.1.2 China: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.1.3 China: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.1.4 China: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.2 Japan:
Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.2.1 Japan: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.2.2 Japan: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.2.3 Japan: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.2.4 Japan: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.3 South Korea:
Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.3.1 South Korea: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.3.2 South Korea: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.3.3 South Korea: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.3.4 South Korea: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.4 India:
Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.4.1 India: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.4.2 India: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.4.3 India: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.4.4 India: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.5 Australia:
Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.5.1 Australia: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.5.2 Australia: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.5.3 Australia: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.5.4 Australia: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.6 New Zealand:
Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.6.1 New Zealand: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.6.2 New Zealand: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.6.3 New Zealand: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.6.4 New Zealand: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.7 Indonesia:
Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.7.1 Indonesia: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.7.2 Indonesia: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.7.3 Indonesia: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.7.4 Indonesia: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.8 Malaysia:
Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.8.1 Malaysia: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.8.2 Malaysia: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.8.3 Malaysia: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.8.4 Malaysia: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.9 Philippines:
Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.9.1 Philippines: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.9.2 Philippines: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.9.3 Philippines: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.9.4 Philippines: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.10 Singapore:
Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.10.1 Singapore: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.10.2 Singapore: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.10.3 Singapore: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.10.4 Singapore: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.11 Thailand:
Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.11.1 Thailand: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.11.2 Thailand: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.11.3 Thailand: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.11.4 Thailand: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.12 Vietnam:
Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.12.1 Vietnam: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.12.2 Vietnam: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.12.3 Vietnam: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.12.4 Vietnam: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.13 Taiwan:
Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.13.1 Taiwan: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.13.2 Taiwan: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.13.3 Taiwan: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.13.4 Taiwan: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Sales Channel
- 11.2.1.14 Bangladesh:
Asia Pacific Cancer Hormone Therapy Market – Revenue and Forecast to 2031 (US$ Million)
- 11.2.1.14.1 Bangladesh: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Drug Class
- 11.2.1.14.2 Bangladesh: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Cancer Type
- 11.2.1.14.3 Bangladesh: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Route of Administration
- 11.2.1.14.4 Bangladesh: Asia Pacific Cancer Hormone Therapy Market Breakdown, by Sales Channel
12. Competitive Landscape
12.1 Heat Map Analysis
12.2 Company Positioning and Concentration
13. Industry Landscape
13.1 Overview
13.2 Market Initiative
13.3 Partnerships and Collaborations
13.4 Other Developments
14. Company Profiles
14.1 Pfizer Inc
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
14.2 AbbVie
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
14.3 Johnson & Johnson
- 14.3.1 Key Facts
- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
14.4 Novartis AG
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
14.5 AstraZeneca
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
14.6 Sanofi
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 SWOT Analysis
- 14.6.6 Key Developments
14.7 Eli Lilly and Co
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
14.8 F. Hoffmann-La Roche Ltd
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
14.9 Astellas Pharma Inc
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments
14.10 Ipsen Pharma
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
15. Appendix
15.1 About Business Market Insights
15.2 List of Abbreviations